Astra saw £14.4bn wiped off its value after Chinese media said dozens of managers were implicated in a scandal.

An insurance fraud investigation linked to AstraZeneca (AZN) expands in China involving dozens of senior executives. Read ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca stock tumbles as Chinese probe widens, implicating executives in insurance fraud and drug import violations ...

AstraZeneca (AZN) stock falls as a Chinese probe into drug importations and data privacy implicates senior and former ...

AstraZeneca said its China president Leon Wang is under investigation and the drugmaker would cooperate with Chinese ...

The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...

AstraZeneca’s China president is under investigation in mainland China, the drug company said on Wednesday. Leon Wang was ...

Investigation of AstraZeneca’s China president prompts industry calls for more transparency; ‘this is only going to get worse ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...